首页 列表页面
Neoadjuvant immunotherapy for NSCLC: Is it time to finally stop saving our best for last?
会议
Neoadjuvant immunotherapy for NSCLC: Is it time to finally stop saving our best for last? John V. Heymach MD, PhD
会议
Tumor mutation burden (TMB) as a biomarker for clinical bene t from dual immune checkpoint blockade with nivolumab (nivo)
+ ipilimumab (ipi) in rst-line (1L) non-small cell lung cancer (NSCLC): Identi cation of TMB cuto from CheckMate 568.
会议
Tumor mutation burden (TMB) as a biomarker for clinical bene t from dual immune checkpoint blockade with nivolumab (nivo)
+ ipilimumab (ipi) in rst-line (1L) non-small cell lung cancer (NSCLC): Identi cation of TMB cuto from CheckMate 568
会议
Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as rst-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): Initial results from CheckMate 227
会议
Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as rst-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): Initial results from CheckMate 227
会议
PFS results for atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) across PD-L1 expression subgroups de ned by the SP142 and SP263 IHC assays con rm all-comer bene t in 1L metastatic NSCLC (mNSCLC)
会议
PFS results for atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) across PD-L1 expression subgroups de ned by the SP142 and SP263 IHC assays con rm all-comer bene t in 1L metastatic NSCLC (mNSCLC)
会议
